Originally published as JCO Early Release 10.1200/JCO.2005.02.113 on July 11 2005

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bosset, J.-F. Articles by Collette, L. Search for Related Content PubMed PubMed Citation Articles by Bosset, J.-F. Articles by Collette, L. Related Articles Related Editorial Social Bookmarking                            What's this?

Enhanced Tumorocidal Effect of Chemotherapy With Preoperative Radiotherapy for Rectal Cancer: Preliminary Results—EORTC 22921

From the Centre Hospitalier Universitaire (CHU) Besançon, Besançon; CHU Tours, Tours; Clinic Avignon, Avignon; Cancer Center Dijon, Dijon; CHU Poitiers, Poitiers; Cancer Center Nantes, Nantes, France; Institut for Oncology and Radiology, Belgrad, Serbia; Rambam Medical Center Haïfa, Haïfa, Israël; and European Organisation for Research and Treatment of Cancer Data Center, Brussels, Belgium

Address reprint requests to Jean-François Bosset, MD, Besançon University Hospital, Department of Radiotherapy, Blvd Fleming, F-25030 Besançon Cedex, France; e-mail: jean-francois.bosset{at}ufc-chu.univ-fcomte.fr

PURPOSE: The European Organisation for Research and Treatment of Cancer (EORTC) trial evaluated the addition of chemotherapy (CT) to preoperative radiation (preop RT) and the value of postoperative CT for improving the survival in patients with T3-4 resectable rectal cancer. Patients were allocated to the following four arms: arm 1, preop RT 45 Gy in 5 weeks; arm 2, preop RT plus two 5-day CT courses (fluorouracil 350 mg/m²/d and leucovorin 20 mg/m²/d) in the first and fifth week of RT; arm 3, preop RT plus four postoperative CT courses; and arm 4, preop RT and CT plus postoperative CT. We investigated the effect of adding CT on the pathologic parameters.

PATIENTS AND METHODS: One thousand eleven patients were entered onto the trial; 505 received preop RT (arms 1 and 3), and 506 received preop RT-CT (arms 2 and 4). We analyzed the differences in tumor size, tumor node stage, number of retrieved nodes, and histologic features such as lymphatic, venous, and perineural invasions, tumor differentiation, and tumor type.

RESULTS: After preop RT-CT, tumors were smaller (P < .0001), had less advanced pT (P < .001) and pN stages (P < .001), had small numbers of examined nodes (P = .046), and less frequent LVN invasions (P .008). Mucinous tumors increased after preop RT-CT (P < .001).

CONCLUSION: In patients with rectal cancer, preliminary results of EORTC Trial 22921 indicate that the addition of CT to preop RT induces downsizing, downstaging, and significant changes in histologic characteristics. Longer follow-up is needed to assess the impact on local control and survival.

Supported by grant Nos. 2U10 CA11488-21 through 5U10 CA11488-34 from the National Cancer Institute (Bethesda, MD) and by Programme Hospitalier de Recherche Clinique (PHRC 1992-France).

Presented at the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, June 5-8, 2004.

The contents of this article are solely the responsibility of the authors and do not necessarily reflect the official views of the National Cancer Institute.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Editorial

• Combined-Modality Neoadjuvant Therapy for Rectal Cancer
  Michael J. O'Connell
  JCO 2005 23: 5450-5451 [Full Text]

This article has been cited by other articles:

				M. S. Roh, L. H. Colangelo, M. J. O'Connell, G. Yothers, M. Deutsch, C. J. Allegra, M. S. Kahlenberg, L. Baez-Diaz, C. S. Ursiny, N. J. Petrelli, et al. Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients With Carcinoma of the Rectum: NSABP R-03 J. Clin. Oncol., November 1, 2009; 27(31): 5124 - 5130. [Abstract] [Full Text] [PDF]

				A. Debucquoy, K. Haustermans, A. Daemen, S. Aydin, L. Libbrecht, O. Gevaert, B. De Moor, S. Tejpar, W. H. McBride, F. Penninckx, et al. Molecular Response to Cetuximab and Efficacy of Preoperative Cetuximab-Based Chemoradiation in Rectal Cancer J. Clin. Oncol., June 10, 2009; 27(17): 2751 - 2757. [Abstract] [Full Text] [PDF]

				I. D. Nagtegaal and P. Quirke What Is the Role for the Circumferential Margin in the Modern Treatment of Rectal Cancer? J. Clin. Oncol., January 10, 2008; 26(2): 303 - 312. [Abstract] [Full Text] [PDF]

				C. G. Willett, B. G. Czito, and J. C. Bendell Radiation Therapy in Stage II and III Rectal Cancer Clin. Cancer Res., November 15, 2007; 13(22): 6903s - 6908s. [Abstract] [Full Text] [PDF]

				R. Glynne-Jones and M. Harrison Locally Advanced Rectal Cancer: What Is the Evidence for Induction Chemoradiation? Oncologist, November 1, 2007; 12(11): 1309 - 1318. [Abstract] [Full Text] [PDF]

				L. Collette, J.-F. Bosset, M. den Dulk, F. Nguyen, L. Mineur, P. Maingon, L. Radosevic-Jelic, M. Pierart, and G. Calais Patients With Curative Resection of cT3-4 Rectal Cancer After Preoperative Radiotherapy or Radiochemotherapy: Does Anybody Benefit From Adjuvant Fluorouracil-Based Chemotherapy? A Trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group J. Clin. Oncol., October 1, 2007; 25(28): 4379 - 4386. [Abstract] [Full Text] [PDF]

				J-P Machiels, C Sempoux, P Scalliet, J-C Coche, Y Humblet, E Van Cutsem, J Kerger, J-L Canon, M Peeters, S Aydin, et al. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer Ann. Onc., April 1, 2007; 18(4): 738 - 744. [Abstract] [Full Text] [PDF]

				J.-P. Gerard, T. Conroy, F. Bonnetain, O. Bouche, O. Chapet, M.-T. Closon-Dejardin, M. Untereiner, B. Leduc, E. Francois, J. Maurel, et al. Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203 J. Clin. Oncol., October 1, 2006; 24(28): 4620 - 4625. [Abstract] [Full Text] [PDF]

				J.-F. Bosset, L. Collette, G. Calais, L. Mineur, P. Maingon, L. Radosevic-Jelic, A. Daban, E. Bardet, A. Beny, J.-C. Ollier, et al. Chemotherapy with Preoperative Radiotherapy in Rectal Cancer N. Engl. J. Med., September 14, 2006; 355(11): 1114 - 1123. [Abstract] [Full Text] [PDF]

				F. A. Calvo, F. J. Serrano, J. A. Diaz-Gonzalez, M. Gomez-Espi, E. Lozano, R. Garcia, D. de la Mata, J. A. Arranz, P. Garcia-Alfonso, G. Perez-Manga, et al. Improved incidence of pT0 downstaged surgical specimens in locally advanced rectal cancer (LARC) treated with induction oxaliplatin plus 5-fluorouracil and preoperative chemoradiation Ann. Onc., July 1, 2006; 17(7): 1103 - 1110. [Abstract] [Full Text] [PDF]

				R. Glynne-Jones, J. Dunst, and D. Sebag-Montefiore The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been? Ann. Onc., March 1, 2006; 17(3): 361 - 371. [Abstract] [Full Text] [PDF]

				A. De Paoli, S. Chiara, G. Luppi, M. L. Friso, G. D. Beretta, S. Del Prete, L. Pasetto, M. Santantonio, E. Sarti, G. Mantello, et al. Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study Ann. Onc., February 1, 2006; 17(2): 246 - 251. [Abstract] [Full Text] [PDF]

				M. J. O'Connell Combined-Modality Neoadjuvant Therapy for Rectal Cancer J. Clin. Oncol., August 20, 2005; 23(24): 5450 - 5451. [Full Text] [PDF]